Skip to Content

Mvasi Approval History

FDA Approved: Yes (First approved September 14, 2017)
Brand name: Mvasi
Generic name: bevacizumab-awwb
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Non-Small Cell Lung Cancer, Colorectal Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer

Mvasi (bevacizumab-awwb) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer.

Development History and FDA Approval Process for Mvasi

DateArticle
Sep 14, 2017Approval FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
Nov 15, 2016Amgen and Allergan Submit Biosimilar BLA for ABP 215 to U.S. FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide